Meta-analysis of large randomised clinical trials of SGLT-2 inhibition indicates that cardiovascular benefits of SGLT-2 inhibition, particularly reducing the risk of cardiovascular death or hospitalisation for heart failure, are present irrespective of trial-level average eGFR [4]. Here, SLC5A2 is linked to heart failure.